Butylphthalide Soft Capsules And Nimodipine Treatment Of Vascular Dementia After Stroke Effect Assessment

Objective: Vascular dementia refers to a variety of cerebral vascular disease due to brain damage:the memory and calculation, language, thinking skills, visual spatial ability decline. With the development of society, people's living standard improves,the population aging has increasingly prominent, with vascular dementia is also on the increasing.Which not only seriously affects the quality patient's live, but also affects the family and society .Vascular dementia is the only hope for prevention and treatment ,so is the research focus at home and abroad.Butylphthalide Soft Capsules is a new anti-ischemic drug, is the fouth self-developd drug in our coutry,and is the firstâ… chemical drug with independent property in the field of cereb- rovascular disease in China. Throughâ…¡,â…¢,â…£clinical test, butylphthalide soft capsules has great efficacy in the treatment of cerebral infarction. And is included in "China's disease prevention and treatment of cerebral blood Guide ".Butylphthalide soft capsules' active ingredient is dl-3-butyl phthalide, is the synthetic racemates, and the same as the structure extracted from celery seed. Numerous studies have shown that it has obvious role in acute ischemic stroke. And widely used in clinical ischemic cerebrovascular disease treatment with a significant effect. It can reconstruct microcirculation in ischemic area ,protect mitochondrial function and restore brain energy metabolism, and also has anti-thrombosis and anti-platelet aggregation effect. Butylphthalide is used for secondary prevention of cerebral infarction is safe and effective. But about vascular dementia's study is few.This test is Butylphthalide Soft Capsules treatment of vascular dementia prospective study. Comparison with nimodipine and using modern technology evaluates its effect and safety in treating vascular dementia after stroke.Methods: The test is cerebral infarction 3 months to 12 months conform to the DSM -IV standard as research object, In comparison with Nimodipine of a randomized,open test. Total of 66 cases randomly divided into experimental group (butylphthalide soft capsule group) and control group (nimodipine tablets group) each of 33 cases . Gave drug method:butylphthalide soft capsule: 600mg/day (100mg/capsules, 2 capsules / time, 3 times a day, three meals a day before the oral administration of 1). Nimodipine tablets120mg/day (20mg/tablets, 2 tablet/time, 3 times a day, three meals a day 1 after the oral administration)for 6 months. Follow-up of patients is after the group first 1 month, 3 months and 6 months for 3 times.Follow-up include: 1) of patients with drug use; whether the relevant laboratory (abnormal liver function) abnormalities; of adverse events; the presence of new cerebral infarction, cerebral hemorrhage and other circumstances in order to determine the compliance of patients Sexual and drug safety. 2)using the scale (MMSE scale, MOCA scale) and daily living scale (ADL scale) evaluate patient's cognitive function .Results: 62 patients completed the final test.Each group 31 patients. Fall of 4 cases.After treatment, 3 times a follow-up MMSE, MoCA, ADL score before treatment were significantly improved, the difference was statistically significant (p <0.05). 3 times between each follow-up MMSE, MOCA, ADL scores were difference was statistically significant (P <0.05). Between the two groups of patients before treatment, MMSE, MoCA, ADL score showed no significant difference (p> 0.05), 3 follow-up after treatment MMSE, MoCA, and ADL scores showed significant difference (p <0.05). Security, the test group, 1 case of cerebral infarction recurrence and in the control group with 2 patients, relapse rate was no significant difference (p> 0.05). 3 patients were off because of recurrence of cerebral infarction, the other 1 case of butylphthalide group off for economic reasons.Butylphthalide adverse reactions were abnormal liver function, to alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased mainly mild and moderate. Gastrointestinal symptoms are rare mainly nausea, heartburn, diarrhea. In this experiment, the experimental group had 1 case of cerebral infarction recurrence, the analysis considers the basis of the blood vessels in patients with poor control of blood pressure is not good about, and that has nothing to do with the test drugs. The main side effects of nimodipine for the drop in blood pressure, skin irritation, gastrointestinal bleeding, thrombocytopenia, even to a transient dizziness, headache, nausea. This test that nimodipine group's incidence of hypotension is higher than Butylphthalide group.But throug adjusts other drugs the symptoms disappeared. The control group, 2 cases of cerebral infarction recurrence, consider the basis of the blood vessels in patients with poor control of blood pressure and blood lipids is not good on, that has nothing to do with the test drugs. The other adverse events of two groups that were unrelated to study drug by analysis.Conclusion: Butylphthalide soft capsule and nimodipine treatment of vascular dementia both have a certain effect.But butylphthalide Soft Capsules is much better than the effect of nimodipine, and fewer adverse reactions, good security. With the medication time, the effect is more significant.